SG3 Management’s Arcturus Therapeutics ARCT Stock Holding History

SG3 Management’s Portfolio ARCT Stock Details ARCT Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2020 Q4	–	Sell	-9,697	Closed	-$416K	–	1008
2020 Q3	$416K	Buy	+9,697	New	+$481K	0.02%	603

Other funds holding ARCT

AIM

ARK Investment Management St. Petersburg, Florida $12.9B AUM 64.92% 1-Year Est. Return

Federated Hermes Pittsburgh, Pennsylvania $61.5B AUM 30.7% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return

Bank Julius Baer & Co Zurich, Switzerland $33.2B AUM 25.01% 1-Year Est. Return

SG3 Management's ARCT Position: Q4 2020 in Review

SG3 Management sold out of Arcturus Therapeutics (ARCT) in Q4 2020, closing a stake of 9,697 shares — an estimated $416K sold.

SG3 Management first reported a position in ARCT in Q3 2020 and held it in 1 quarter. The position peaked at $416K in Q3 2020. 135 funds tracked by Wall St. Rank hold ARCT as of Q4 2020.

SG3 Management reported no remaining Arcturus Therapeutics position as of Q4 2020 after selling out during the quarter.
SG3 Management sold 9,697 Arcturus Therapeutics shares in Q4 2020, an estimated $416K.
SG3 Management first reported a position in Arcturus Therapeutics in Q3 2020 and held it in 1 quarter.
SG3 Management's Arcturus Therapeutics position peaked at $416K in Q3 2020.
135 funds tracked by Wall St. Rank held Arcturus Therapeutics as of Q4 2020.

Based on SG3 Management's 13F filing for Q4 2020, filed 16 Feb 2021.